Aptinyx (APTX) Reports Q3 Loss of $0.31/sh
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/23/2026
- Wall St rises on the day but falls for the week; bond yields and Iran in focus
- UBS says bull market has further to run
- S&P 500 may pull back before midterms, but Citi says buy the dip
- Global yield relief evaporates as U.S. rates push back toward multi-decade peaks
- BofA's Hartnett sees dollar slump, risk selloff if bond intervention fails
- Applied Optoelectronics sets up $600M at-the-market stock offering
- Fannie Mae loses at least 10 senior executives amid departures - WSJ
- Wall St rises on the day but falls for the week; bond yields and Iran in focus
- Morgan Stanley course-corrects their semiconductor equipment outlook on demand
- One killed, three injured when man attacks Swedish school with sword
Aptinyx Reports Third Quarter 2021 Financial Results and Recent Highlights
November 9, 2021 4:05 PM ESTCompleted enrollment in Phase 2b study of NYX-2925 in patients with painful diabetic peripheral neuropathy; results expected in early to mid 2Q 2022
Phase 2b fibromyalgia study and exploratory Phase 2 cognitive impairment study remain on track for readouts in 2022
PTSD Phase 2b program is set to initiate in 4Q 2021
Strong balance sheet supports Phase 2 data readouts from all four clinical development programs
Management to host conference call today at 5:00 p.m. ET
EVANSTON, Ill.--(BUSINESS WIRE)-- Aptinyx Inc. (Nasdaq:... More
